Stock Market Reviews

CMND (Clearmind Medicine Inc.) News

Get the latest news, insights, and market updates on CMND (Clearmind Medicine Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• BC-Most Active Stocks
  Nu Holdings Ltd. 37,382,822 15.675
  Nov 18, 2025 - $CMND
• Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
  Vancouver, Canada, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced positive top-line results from the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate for the
  Nov 18, 2025 - $CMND
• Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
  Vancouver, Canada, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of an Israeli patent application for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing
  Nov 17, 2025 - $CMND
• BC-Most Active Stocks
  EPWK Holdings Ltd. 33,767,461 0.0455
  Nov 13, 2025 - $CMND
• Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
  Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug ca
  Nov 13, 2025 - $CMND
• Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment
  The notice was received by the China National Intellectual Property Administration Vancouver, Canada, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced notice of publication by the China National Intellectual Property Administration, referring to the Comp
  Nov 12, 2025 - $CMND
• Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
  Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032 Vancouver, Canada, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced that it has successfully completed treatment of th
  Nov 10, 2025 - $CMND
• Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
  The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notification Letter Vancouver, Canada, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems,
  Nov 6, 2025 - $CMND
• Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing
  Patent expands MEAI’s global intellectual property protection as Clearmind advances clinical development and commercialization plans Vancouver, Canada, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a patent application in South Korea cov
  Nov 5, 2025 - $CMND
• Weekly Roundup on the Cannabis Sector & Psychedelic Sector
  Key Takeaways; Cannabis Sector Verano Holdings Ended Legal Battle with Vireo Growth; The Company Also Reported Third Quarter 2025 Financial Results Jushi Holdings’ Subsidiary is Targeting DoorDash and Total Wine in Landmark Lawsuit Over Illegal Hemp THC Sales Key Takeaways; Psychedelic Sector Compass Pathways Expanded Leadership and Research to Advance Precision Mental Health Treatments Clearmind […]
  Nov 2, 2025 - $CMND